Combination Use of First-Line Afatinib and Proton-Pump Inhibitors Reduces Overall Survival Among Patients with EGFFR Mutant Lung Cancer.

Publication Year: 2022

DOI:
10.2147/OTT.S387165

PMCID:
PMC9805747

PMID:
36597496

Journal Information

Full Title: Onco Targets Ther

Abbreviation: Onco Targets Ther

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure The authors have no conflicts of interest relevant to this article."

Evidence found in paper:

"This study was supported by a grant from Chang Gung Memorial Hospital, Chia-Yi branch, Taiwan (CGRPG6K0041). This funding body played no role in the study design, analysis, and interpretation of data in this paper."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025